Gourt > Health > Pharmacy > Drugs and Medications > E > Efavirenz
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
More on [ Efavirenz ]
Mylan Inc awarded tentative FDA approval for NDA for Efavirenz Tablets for HIV ...: These innovative paediatric.. http://bit.ly/6ksEfx
bathhouseindex (Bath House Index) Wed, 23 Dec 2009 11:57:19 -0000
Mylan Inc awarded tentative FDA approval for NDA for Efavirenz Tablets for HIV ...: These innovative paediatric.. http://bit.ly/6ksEfx
Mylan Inc awarded tentative FDA approval for NDA for Efavirenz Tablets for HIV ... http://bit.ly/5BmfUL
CancerLeft (Cancer Left) Wed, 23 Dec 2009 10:50:32 -0000
Mylan Inc awarded tentative FDA approval for NDA for Efavirenz Tablets for HIV ... http://bit.ly/5BmfUL
HIV/AIDS News: Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR: Mylan Inc. today... http://bit.ly/8Rmpkl
HIVAIDS_News (News-Medical.Net) Tue, 22 Dec 2009 17:24:17 -0000
HIV/AIDS News: Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR: Mylan Inc. today... http://bit.ly/8Rmpkl
Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR: Mylan Inc. today announced that... http://bit.ly/8Rmpkl
NewsMedical (News-Medical.Net) Tue, 22 Dec 2009 14:03:01 -0000
Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR: Mylan Inc. today announced that... http://bit.ly/8Rmpkl
News: Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR http://bit.ly/5TT9T3
UsHour (UsHour) Tue, 22 Dec 2009 13:47:39 -0000
News: Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR http://bit.ly/5TT9T3
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' NDA for Efavirenz Tablets http://bit.ly/6q5bHl
PharmProEditor (Mike Auerbach) Tue, 22 Dec 2009 13:35:43 -0000
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' NDA for Efavirenz Tablets http://bit.ly/6q5bHl
DrugDigest: Efavirenz ( Sustiva ) - Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.
Sustiva - A non-nucleoside reverse transcriptase inhibitor.
Sustiva - a.k.a. Efavirenz, DMP-266.
| ARV Abuse in South Africa News Report | |
| Next Video | |
